Dr. Hsing-Mao Chu, CEO at T-E Meds, will be presenting at the prestigious World ADC conference in San Diego on October 16th (Monday) from 4:30 PM to 5:00 PM.
He will unveil our groundbreaking joint technology of “Drug Bundles” and “Glycan Modification” in the applications of ADCs. He will also show how this innovative approach enables precise site-specific conjugation through a straightforward process, resulting in the creation of homogeneous ADCs with a remarkable Drug-to-Antibody Ratio (DAR). In our flexible designs, including dual-payload and bispecific ADCs, are redefining the future of targeted therapy.
Don’t miss this golden opportunity to elevate your understanding of ADCs and be at the forefront of medical innovation!
See you there!
